

UGN-101 reviewed in real-world upper tract urothelial cancer setting

January 9 2023, by Elana Gotkine



For patients with upper tract urothelial cancers (UTUCs), the novel

therapeutic UGN-101 seems to be effective, with an acceptable safety profile, according to research published online Nov. 22 in *Urologic Oncology*.

Solomon L. Woldu, M.D., from the University of Texas Southwestern Medical Center in Dallas, and colleagues conducted a retrospective review of all UGN-101 cases from 15 institutions, focusing on practice patterns, efficacy, and adverse effects. A total of 136 renal units treated from 132 patients were included, with most cases being biopsy-proven low-grade UTUC.

The researchers observed [considerable variation](#) in [practice patterns](#); antegrade instillation via a percutaneous nephrostomy was the most common administration technique. Sixty-nine percent of patients were disease-free at the time of first endoscopic evaluation when UGN-101 was utilized in the adjuvant setting, while 37 percent were endoscopically clear on the first evaluation with UGN-101 use in the chemoablative setting.

In [patients](#) with smaller tumor size prior to UGN-101 induction, complete response was higher; a 70 percent complete response was seen in association with low-volume (

Citation: UGN-101 reviewed in real-world upper tract urothelial cancer setting (2023, January 9) retrieved 2 May 2024 from

<https://medicalxpress.com/news/2023-01-ugn-real-world-upper-tract-urothelial.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
